Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Edward E. Bondi is active.

Publication


Featured researches published by Edward E. Bondi.


Cancer Research | 1985

Characteristics of Cultured Human Melanocytes Isolated from Different Stages of Tumor Progression

Meenhard Herlyn; Jan Thurin; Gloria Balaban; Jeannette L. Bennicelli; Dorothee Herlyn; David E. Elder; Edward E. Bondi; DuPont Guerry; Peter C. Nowell; Wallace H. Clark; Hilary Koprowski

Normal melanocytes and melanocytes of normal nevi, primary melanoma in the radial (RGP) and vertical (VGP) growth phases, and metastatic melanoma exhibited and maintained phenotypic differences when grown in tissue culture or in experimental animals. Only metastatic and VGP primary melanoma cells were tumorigenic in athymic nude mice and had nonrandom chromosomal abnormalities involving chromosomes 1, 6, and 7. The colony-forming efficiency in soft agar was also highest in these two cell types. A cell line of RGP primary melanoma had characteristics of both benign and malignant cells: nevus-like morphology; nontumorigenicity in nude mice; but karyotypic abnormality of chromosome 6. It also had a ganglioside pattern similar to that of normal melanocytes but not melanomas, i.e., a high GM3 ganglioside content compared to the amounts of GM2, GD2, and GD3 gangliosides. Binding of monoclonal antibodies secreted by hybridomas generated by immunization of mice with VGP primary and metastatic melanoma was highest with cells and supernatants of cultures from advanced melanoma and least with nevus cells. There was no binding to normal melanocytes except with the monoclonal antibodies specific for nerve growth factor receptor or 9-O-acetyl-GD3 ganglioside. On the other hand, monoclonal anti-nevus antibodies bound to melanocytes, nevus cells, and RGP primary melanoma cells but not to VGP primary or metastatic melanoma cells. Cultured human melanocytic cells appear to be a unique model for the study of tumor progression.


Cancer | 1985

The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51—3.99 mm)

David E. Elder; DuPont Guerry; Marie Vanhorn; Shelley Hurwitz; Lee M. Zehngebot; Leonard I. Goldman; Donato LaRossa; Ralph Hamilton; Edward E. Bondi; Wallace H. Clark

The survival times of patients who had an elective regional lymph node dissection was compared with that of those who did not undergo the procedure in a database of 72 patients with clinical Stage I melanoma of intermediate thickness (1.51–3.99 mm). All of the patients had been followed for 5 years or longer or until death. No significant differences were found in other reported prognostic factors, suggesting that the two groups were comparable. By multivariate analysis, a low mitotic rate, intermediate patient age, and the presence of an infiltrative lymphocytic response were found to be associated with favorable survival. There did not appear to be any association of elective regional lymph node dissection with survival; and it was concluded that such therapy should not be regarded as “standard” for clinical Stage I melanoma of intermediate thickness.


American Journal of Ophthalmology | 1984

Lack of Association Between Intraocular Melanoma and Cutaneous Dysplastic Nevi

Marcia R. Taylor; DuPont Guerry; Edward E. Bondi; Jerry A. Shields; James J. Augsburger; Edward J. Lusk; David E. Elder; Wallace H. Clark; Marie Van Horn

The occurrence of uveal and cutaneous malignant melanoma and the dysplastic nevus syndrome in the same individual suggests an etiologic relationship among these diseases. Thus, the dysplastic nevus syndrome could be viewed as marking an increased risk of both cutaneous and ocular melanoma. We postulated that if such a relationship exists, patients with both forms of melanoma should have a high prevalence of dysplastic nevi. We examined 44 patients (31 women and 13 men ranging in age from 20 to 80 years) with uveal melanoma for evidence of cutaneous melanoma and dysplastic nevi. We also examined photographs of 46 patients (24 men and 22 women ranging in age from 19 to 67 years) with nonfamilial cutaneous melanoma to determine the prevalence of dysplastic nevi. We found a 4.5% prevalence of dysplastic nevi in patients with uveal melanoma, significantly lower than the 41% prevalence in patients with cutaneous melanoma (two of 44 patients vs 19 of 46 patients). This study indicates that uveal and cutaneous melanoma are not etiologically linked through dysplastic nevi and suggests that patients with uveal melanoma are no more likely to have cutaneous dysplastic nevi than the general population.


Archives of Dermatology | 1987

Target Blue Nevi-Reply

Edward E. Bondi

In Reply.— I appreciate Dr Gartmanns additional references from the German-language literature to the cockade like, or target blue nevus. I also agree that this is not a rare finding. I have now observed other cases of this target like pigmentation in blue nevi, and even more cases of cellular blue nevi that possess focal areas that are devoid of pigment. Certainly, a change or loss of pigmentation in blue nevus is an indication for surgical removal, but I think it is most frequently a benign process occurring during the maturation of many blue nevi. Why it so commonly takes a distinctive target pattern on the dorsal aspect of the hands and feet remains a puzzle.


Cancer Research | 1980

Specific Immunoreactivity of Hybridoma-secreted Monoclonal Anti-Melanoma Antibodies to Cultured Cells and Freshly Derived Human Cells

Meenhard Herlyn; Wallace H. Clark; Michael J. Mastrangelo; DuPont Guerry; David E. Elder; Donato LaRossa; Ralph Hamilton; Edward E. Bondi; Ralph J. Tuthill; Zenon Steplewski; Hilary Koprowski


Cancer Research | 1983

Phenotypic Characteristics of Cells Derived from Precursors of Human Melanoma

Meenhard Herlyn; Dorothee Herlyn; David E. Elder; Edward E. Bondi; Donato LaRossa; Ralph Hamilton; Henry F. Sears; Gloria Balaban; DuPont Guerry; Wallace H. Clark; Hilary Koprowski


Archives of Dermatology | 1982

Malignant Angioendotheliomatosis Proliferans Treated With Doxorubicin

Thomas M. Keahey; DuPont Guerry; Ralph J. Tuthill; Edward E. Bondi


Archives of Dermatology | 1981

Topical Chemotherapy of Dysplastic Melanocytic Nevi With 5% Fluorouracil

Edward E. Bondi; Wallace H. Clark; David E. Elder; DuPont Guerry; Mark H. Greene


Archives of Dermatology | 1979

Psoriasis Overlying an Epidermal Nevus

Edward E. Bondi


JAMA | 1983

Skin markings in malignant melanoma.

Edward E. Bondi; David E. Elder; DuPont Guerry; Wallace H. Clark

Collaboration


Dive into the Edward E. Bondi's collaboration.

Top Co-Authors

Avatar

DuPont Guerry

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Wallace H. Clark

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

David E. Elder

Hospital of the University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Hilary Koprowski

Thomas Jefferson University

View shared research outputs
Top Co-Authors

Avatar

Donato LaRossa

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ralph Hamilton

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Gloria Balaban

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge